BCM
SCMP

Brookstone Capital Management’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Brookstone Capital Management’s Portfolio SCMP Stock Details SCMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-368
Closed -$6K – 2225
2015
Q2 		$6K Buy
+368
New +$6.38K ﹤0.01% 1441

Other funds holding SCMP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BIM
Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return
RFC
Russell Frank Company Seattle, Washington $56.9B AUM 2.13% 1-Year Est. Return

Brookstone Capital Management's SCMP Position: Q3 2015 in Review

Brookstone Capital Management sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q3 2015, closing a stake of 368 shares — an estimated $6K sold.

Brookstone Capital Management first reported a position in SCMP in Q2 2015 and held it in 1 quarter. The position peaked at $6K in Q2 2015. 154 funds tracked by Wall St. Rank hold SCMP as of Q3 2015.

  • Brookstone Capital Management reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q3 2015 after selling out during the quarter.
  • Brookstone Capital Management sold 368 Sucampo Pharmaceuticals, Inc. shares in Q3 2015, an estimated $6K.
  • Brookstone Capital Management first reported a position in Sucampo Pharmaceuticals, Inc. in Q2 2015 and held it in 1 quarter.
  • Brookstone Capital Management's Sucampo Pharmaceuticals, Inc. position peaked at $6K in Q2 2015.
  • 154 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q3 2015.

Based on Brookstone Capital Management's 13F filing for Q3 2015, filed 28 Oct 2015.